Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/united-states-adopted-name-usan-council-and-international-nonproprietary-names-inn-expert-committee-recognizes-new-therapeutic-class-by-granting-nibrozetone-as-new-generic-name-for-epicentrxs-lead-small-molecule-nlrp3-inhib-301871261.html
https://www.prnewswire.com/news-releases/epicentrx-presents-updates-on-its-oncology-clinical-development-programs-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting-301841594.html
https://www.prnewswire.com/news-releases/epicentrx-receives-fast-track-designation-from-the-us-fda-for-lead-asset-rrx-001-to-preventattenuate-chemotherapy-and-radiation-treatment-induced-severe-oral-mucositis-301784214.html
https://www.prnewswire.com/news-releases/promising-safety-and-efficacy-signals-from-a-small-phase-1-pilot-study-primetime-with-rrx-001--opdivo-nivolumab-in-traditionally-checkpoint-inhibitor-non-responsive-tumors-301773049.html
https://www.prnewswire.com/news-releases/epicentrx-announces-presentation-for-phase-2-randomized-active-controlled-multicenter-trial-to-assess-the-safety-and-efficacy-of-rrx-001-vs-regorafenib-in-thirdfourth-line-colorectal-cancer-at-the-2023-american-society-of-clin-301726884.html
https://www.fiercebiotech.com/biotech/eyeing-untapped-niche-epicentrx-makes-case-cancer-toxicity-prevention-drug
https://www.prnewswire.com/news-releases/epicentrx-publishes-phase-2-results-for-rrx-001-as-an-anti-mucositis-agent-in-patients-receiving-radiation-for-head-and-neck-cancers-301726334.html
https://www.prnewswire.com/news-releases/rrx-001--irinotecan-significantly-improved-progression-free-survival-pfs-versus-regorafenib-in-the-randomized-phase-2-rocket-trial-in-advanced-colorectal-cancer-301702337.html
https://www.prnewswire.com/news-releases/epicentrx-announces-patent-issued-for-radiation-protection-with-rrx-001-in-combination-regimens-301695211.html
https://www.prnewswire.com/news-releases/epicentrx-awarded-funding-from-fightmnd-to-evaluate-therapeutic-potential-of-rrx-001-in-motor-neuron-disease-aka-als-301688321.html